DK1345620T3 - Stabiliseret sammensætning til sårdebridering - Google Patents

Stabiliseret sammensætning til sårdebridering

Info

Publication number
DK1345620T3
DK1345620T3 DK01962345T DK01962345T DK1345620T3 DK 1345620 T3 DK1345620 T3 DK 1345620T3 DK 01962345 T DK01962345 T DK 01962345T DK 01962345 T DK01962345 T DK 01962345T DK 1345620 T3 DK1345620 T3 DK 1345620T3
Authority
DK
Denmark
Prior art keywords
stabilized composition
wound debridement
wound
anhydrous hydrophilic
debridement
Prior art date
Application number
DK01962345T
Other languages
Danish (da)
English (en)
Inventor
David W Hobson
David P Jones
Katarzyna Koster
Pilar P Duque
Original Assignee
Healthpoint Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healthpoint Ltd filed Critical Healthpoint Ltd
Application granted granted Critical
Publication of DK1345620T3 publication Critical patent/DK1345620T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Enzymes And Modification Thereof (AREA)
DK01962345T 2000-12-27 2001-08-06 Stabiliseret sammensætning til sårdebridering DK1345620T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/749,217 US6548556B2 (en) 2000-12-27 2000-12-27 Stable enzymatic wound debrider
PCT/US2001/041558 WO2002051436A2 (en) 2000-12-27 2001-08-06 Stable enzymatic wound debrider

Publications (1)

Publication Number Publication Date
DK1345620T3 true DK1345620T3 (da) 2008-05-13

Family

ID=25012779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01962345T DK1345620T3 (da) 2000-12-27 2001-08-06 Stabiliseret sammensætning til sårdebridering

Country Status (14)

Country Link
US (1) US6548556B2 (es)
EP (1) EP1345620B1 (es)
JP (1) JP4071628B2 (es)
CN (1) CN1230200C (es)
AT (1) ATE381941T1 (es)
AU (1) AU2001283537B2 (es)
CA (1) CA2433080C (es)
DE (1) DE60132113T2 (es)
DK (1) DK1345620T3 (es)
ES (1) ES2296788T3 (es)
HK (1) HK1056834A1 (es)
MX (1) MXPA03005851A (es)
PT (1) PT1345620E (es)
WO (1) WO2002051436A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20030099693A1 (en) * 2001-11-02 2003-05-29 Auffret Anthony David Wafer
US20030198631A1 (en) * 2002-04-18 2003-10-23 Healthpoint, Ltd. Thermolysin enzymatic wound debrider
US7785584B2 (en) * 2003-08-13 2010-08-31 Healthpoint, Ltd. Ointment wound spray
WO2005035010A1 (en) * 2003-10-10 2005-04-21 Coloplast A/S Wound dressing containing proteolytic enzymes
US20050079147A1 (en) * 2003-10-14 2005-04-14 Bernard Delaey Wound healing compositions and uses
US20060182705A1 (en) * 2005-02-11 2006-08-17 Cruse Maria K Composition for reduction and prevention of wrinkles on the skin
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
FR2892949B1 (fr) * 2005-11-08 2008-05-16 Maco Pharma Sa Unite de filtration des leucocytes a adhesion des plaquettes reduites
WO2007075853A2 (en) * 2005-12-20 2007-07-05 Swiss-American Products, Inc. Protease compositions for the treatment of damaged tissue
GB0606921D0 (en) * 2006-04-06 2006-05-17 Insense Ltd Skin dressing
US8754045B2 (en) * 2006-05-12 2014-06-17 James A. Livingston Enzymatic debridement therapy for abnormal cell proliferation
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
EP2226382A1 (en) 2009-03-03 2010-09-08 B.R.A.I.N. Biotechnology Research and Information Network AG Protease for wound conditioning and skin care
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
NZ600403A (en) * 2009-12-08 2014-01-31 Smith & Nephew Orthopaedics Ag Enzymatic wound debriding compositions with enhanced enzymatic activity
EP2580388B1 (en) 2010-06-08 2018-01-17 Buckman Laboratories International, Inc Methods to degrade sludge from pulp and paper manufacturing
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
MX2013013219A (es) 2011-05-12 2014-07-28 Smith & Nephew Orthopaedics Ag Composiciones para el desbridamiento de heridas que contienen seaprosa y metodos para tratar heridas usando esas composiciones.
EP2809341B1 (en) * 2012-02-02 2020-12-30 Galenagen, LLC Enzyme compositions and use thereof for wound healing
BR112014027995A2 (pt) 2012-05-11 2017-06-27 Smith & Nephew Inc uso de seaprose para remover biopelícula bacteriana
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11446364B2 (en) 2012-11-14 2022-09-20 Smith & Nephew, Inc. Stable thermolysin hydrogel
US11452698B2 (en) 2013-03-15 2022-09-27 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
AU2014353853A1 (en) 2013-11-25 2016-07-07 Biomedical Concepts Llc Composition, system and method for treating skin
US9592280B2 (en) 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
US20160101166A1 (en) 2014-10-10 2016-04-14 Rochal Industries, Llp Compositions and kits for treating pruritus and methods of using the same
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
WO2016094675A1 (en) 2014-12-12 2016-06-16 Smith & Nephew, Inc. Use of clostridium histolyticum protease mixture in promoting wound healing
CN105255825B (zh) * 2015-11-16 2019-07-19 广州赛莱拉干细胞科技股份有限公司 一种跟腱来源肌腱干细胞原代分离消化液及分离方法
WO2017130204A1 (en) 2016-01-31 2017-08-03 Mediwound Ltd. Debriding composition for treating wounds
WO2017183018A1 (en) 2016-04-18 2017-10-26 Mediwound Ltd Methods of debridement of chronic wounds
EP3490588A1 (en) 2016-07-27 2019-06-05 Smith&Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
WO2018140707A1 (en) 2017-01-30 2018-08-02 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces
CN106902075A (zh) * 2017-02-23 2017-06-30 任君刚 一种基于无水技术的水敏感粘附性软膏及其制备方法
CN110180019A (zh) * 2019-07-11 2019-08-30 周玉芳 一种提高皮肤修复功能的复合酶及其制备方法
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2917433A (en) 1956-04-02 1959-12-15 Rystan Company Stable aqueous papain topical compositions
US2995493A (en) 1957-04-17 1961-08-08 Johnson & Johnson Ficus enzyme and hydrophilic carrier composition
US3019171A (en) 1957-11-25 1962-01-30 Ethicon Inc Activated enzyme compositions
US3003917A (en) 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
US3409719A (en) 1967-05-23 1968-11-05 Baxter Laboratories Inc Debridement agent
US3860702A (en) 1972-07-11 1975-01-14 Schuyler Dev Corp Anti-inflammatory compositions
US3983209A (en) 1975-01-28 1976-09-28 Alza Corporation Method for treating burns
GB1594389A (en) 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
US4250167A (en) 1978-09-19 1981-02-10 Davis Elgan A Methods for reducing calcium deposits
SE8302268L (sv) 1983-04-22 1984-10-23 Lars G I Hellgren Ny kombination av proteolytiska och lipolytiska enzymer lemplig som tvettkomposition
AU573730B2 (en) 1982-10-25 1988-06-23 Antarctic Pharma Ab Enzyme composition from euphausiaceae (antarctic krill) as cleaning agent
US4668228A (en) 1985-03-12 1987-05-26 Johnson & Johnson Products, Inc. Debriding tape
GB8724728D0 (en) 1987-10-22 1987-11-25 Genzyme Corp Cysteine proteinase
US5206026A (en) 1988-05-24 1993-04-27 Sharik Clyde L Instantaneous delivery film
US5296222A (en) 1989-02-23 1994-03-22 University Of Utah Percutaneous drug delivery system
US5130131A (en) 1989-08-18 1992-07-14 University Of Florida Methods for the control of fungi and bacteria
EP0498532A1 (en) 1991-01-10 1992-08-12 E.R. SQUIBB & SONS, INC. Necrotic tissue debridement powder composition containing a proteolytic enzyme
AU670094B2 (en) 1992-04-23 1996-07-04 Berlex Laboratories, Inc. Bioadhesive solid mineral oil emulsion
US6030612A (en) 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
IL105699A0 (en) 1992-06-26 1993-09-22 Genzyme Corp Hydrophilic creams for delivery of therapeutic agents
AU1939895A (en) 1994-03-01 1995-09-18 E.R. Squibb & Sons, Inc. Enzymatic debridement compositions and methods
US5387517A (en) 1994-03-23 1995-02-07 Ethicon, Inc. Thiol activated protease from stem bromelain for treating devitalized tissue
US5505958A (en) 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
US5494896A (en) 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US5747005A (en) * 1995-08-02 1998-05-05 Barels; Ronald R. Oil-based, anti-plaque dentifrice composition
WO1997009960A1 (en) 1995-09-14 1997-03-20 Sorenson Pharmaceutical, Inc. Composition and method for treating diseased nails
US6017531A (en) 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
JP2002514960A (ja) 1997-06-18 2002-05-21 コヘージョン テクノロジーズ，インコーポレイテッド トロンビンおよびミクロフィブリルコラーゲンを含む組成物、ならびにその調製および使用の方法

Also Published As

Publication number Publication date
CA2433080C (en) 2004-07-06
MXPA03005851A (es) 2004-05-04
PT1345620E (pt) 2008-01-10
HK1056834A1 (en) 2004-03-05
US6548556B2 (en) 2003-04-15
EP1345620B1 (en) 2007-12-26
CA2433080A1 (en) 2002-07-04
WO2002051436A2 (en) 2002-07-04
US20020114798A1 (en) 2002-08-22
DE60132113D1 (de) 2008-02-07
EP1345620A2 (en) 2003-09-24
AU2001283537B2 (en) 2005-04-14
WO2002051436A3 (en) 2002-10-03
ES2296788T3 (es) 2008-05-01
DE60132113T2 (de) 2008-12-18
ATE381941T1 (de) 2008-01-15
CN1494431A (zh) 2004-05-05
JP2004520321A (ja) 2004-07-08
CN1230200C (zh) 2005-12-07
JP4071628B2 (ja) 2008-04-02

Similar Documents

Publication Publication Date Title
DK1345620T3 (da) Stabiliseret sammensætning til sårdebridering
AU2001282438A1 (en) System for enhanced chemical debridement
DE60237162D1 (de) Liposomenladung mit metallionen
DE122012000015I1 (de) Peptidomimetika als protease inhibitoren.
NO20015785L (no) I dets vesentlige oljefrie cyklosporinblandinger
ATE376996T1 (de) Antibakterielle mittel
GB2387696A (en) Real-time odds-based gaming
NO20024221L (no) Blandinger inneholdende alfa-2-adrenerge agonistkomponenter
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
WO2002001644A3 (en) Power mosfet and methods of forming and operating the same
ATE330017T1 (de) Kallikrein gen
TR199902751T2 (xx) Proteaz inhibit�rleri.
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
NO20031860D0 (no) Kahalaolid F
FR2826266B1 (fr) Composition cosmetique ou dermatologique comprenant une association entre un compose de la famille des n-acylaminoamides et au moins un inhibiteur de metalloproteinases matricielles
DE60233891D1 (de) Selektives targeting von apoptotischen zellen
ATE352206T1 (de) Flüssiges brotverbesserungsmittel
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
ATE479420T1 (de) Orale zusammensetzung mit verbesserten mundhygieneeigenschaften
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
DE60124148D1 (de) Kalzilytische verbindungen
ATE361369T1 (de) Adenovirale systeme und deren anwendungen
ATE290878T1 (de) Inhibierung von invasiver remodulierung
Lee et al. Effects of Neurotoxin 6-Aminonicotinamide on Levels of Metabolites and Enzymes in the Plasma of Japanese Quail